VBI Vaccines (VBIV)
(Delayed Data from NSDQ)
$0.09 USD
-0.02 (-18.97%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $0.08 -0.01 (-14.89%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMVBI Vaccines, Inc. (VBIV) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$2.00 | $2.00 | $2.00 | 1,566.67% |
Price Target
Only one analyst offered a short-term price target of $2.00 for VBI Vaccines, Inc. This represents an increase of 1% from the last closing price of $0.12.
Analyst Price Targets (1 )
Broker Rating
Only one brokerage firm provided a Strong Buy-equivalent recommendation for VBI Vaccines, Inc. This translates to an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell). ABR is the calculated average of actual recommendations (Buy, Hold, Sell etc.) made by brokerage firms.
The current ABR compares to an ABR of 1.50 a month ago based on two recommendations. There were one Strong Buy and one Buy recommendations a month ago.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 1 | 1 | 1 | 1 | 1 |
Buy | 0 | 1 | 1 | 1 | 1 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.00 | 1.50 | 1.50 | 1.50 | 1.50 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
Not Identified | Not Identified | Not Identified | Not Identified | Not Identified |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.00 |
ABR (Last week) | 1.50 |
# of Recs in ABR | 1 |
Average Target Price | $2.00 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 91 of 253 |
Current Quarter EPS Est: | NA |